Browsing Pharmacology & Therapeutics by Author "Barry, Michael"
Now showing items 1-12 of 12
-
A study of the impact of highly active antiretroviral therapy on the pharmacoepidemiology and pharmacoeconomics of HIV infection
Ryan, Máirín (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2001)The HIV pandemic has resulted in the most intense and as yet unparalleled effort devoted to antimicrobial drug development ever to be initiated in the developed world. The intensive drug research and development, compressed ... -
Cost-effectiveness of anti-tumour necrosis factor drugs for the treatment of rheumatoid arthritis in Ireland
Adams, Roisin C. (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2012)Rheumatoid Arthritis (RA) is the most common form of inflammatory arthritis. It is a chronic condition that places a substantial burden on patients and their carers, imposing a negative effect on quality of life (QOL), ... -
Health economics in the Irish healthcare setting
Walshe, Valerie E. (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2008)Economic analysis plays a key role in deciding which healthcare interventions should be made available in collectively funded healthcare systems. The aim of this thesis is to examine the application of health economics in ... -
Health technology assessment in the Irish healthcare setting : application to oral anticoagulants
McCullagh, Laura M. (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2012)The objective of this thesis was to examine the application of economic evaluation within the Irish healthcare setting. In so doing, the author sought to develop skills in indirect comparison, economic modelling, value of ... -
Health Technology Assessment of CD19 CAR T-Cell Therapies in the Irish Healthcare Setting.
Carey, Niamh Aisling (Trinity College Dublin. School of Medicine. Discipline of Pharmacology & Therapeutics, 2022)The aim of this research was to undertake health technology assessments of CD19 CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel. A bespoke cost-utility model was developed to examine the cost effectiveness ... -
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
Barry, Michael; Bergin, Colm; Walsh, Cathal (2015)ACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a ... -
Multiple sclerosis in Ireland : costs, health-related quality of life and cost effectiveness of disease-modifying therapies
Fogarty, Emer (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2014)This study aimed to evaluate the economic and health-related quality of life (HRQoL) burden of multiple sclerosis (MS) in Ireland, and to develop a framework for assessing the cost effectiveness of disease-modifying therapies ... -
Pharmaceutical pricing and reimbursement : an Irish perspective
Tilson, Lesley H. (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2006)There has been a five-fold increase in state expenditure on medicines under the Community Drug Schemes in Ireland over the last decade (1994 to 2004). As a result of this marked increase in pharmaceutical expenditure, the ... -
Pharmacoeconomics of Statin Therapy in Ireland
Heerey, Adrienne Monica (Trinity College (Dublin, Ireland). School of Medicine. Discipline of Pharmacology & Therapeutics, 2002)Cardiovascular disease is the leading cause of death in most industrialised countries, including Ireland. Cholesterol lowering by pharmacological intervention prevents atherosclerotic plaque progression and has been shown ... -
The Pharmacokinetic Interaction between Ivacaftor and Ritonavir
LIDDY, ANNE MARIE (Trinity College Dublin. School of Medicine. Discipline of Pharmacology & Therapeutics, 2019)Ivacaftor is the first small molecule for the treatment of cystic fibrosis (CF) that directly targets the inherited defect in the cystic fibrosis transmembrane conductance regulator (CFTR). In phase III clinical trials ...